JP2005503356A - 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用 - Google Patents
環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用 Download PDFInfo
- Publication number
- JP2005503356A JP2005503356A JP2003501989A JP2003501989A JP2005503356A JP 2005503356 A JP2005503356 A JP 2005503356A JP 2003501989 A JP2003501989 A JP 2003501989A JP 2003501989 A JP2003501989 A JP 2003501989A JP 2005503356 A JP2005503356 A JP 2005503356A
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- benzodiazepin
- dimethoxy
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 title claims description 8
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 175
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims description 97
- 125000003118 aryl group Chemical group 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 36
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 30
- 125000001544 thienyl group Chemical group 0.000 claims description 29
- 239000000460 chlorine Substances 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 20
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 150000002430 hydrocarbons Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- CIBFDTUUNLMFMC-UHFFFAOYSA-N 7,8-dimethoxy-1-phenyl-3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)NN=C1C1=CC=CC=C1 CIBFDTUUNLMFMC-UHFFFAOYSA-N 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000002541 furyl group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 229930195733 hydrocarbon Natural products 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- SJABLWFWDKABFZ-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-5-propyl-3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound N1C(=O)C(CCC)C2=CC(OCC)=C(OCC)C=C2C(C=2SC3=CC=CC=C3C=2)=N1 SJABLWFWDKABFZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 150000001350 alkyl halides Chemical class 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052763 palladium Inorganic materials 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 150000003857 carboxamides Chemical class 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004434 sulfur atom Chemical group 0.000 claims description 5
- ASCRLTIXZKFQJI-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-3-ethyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2CC(=O)N(CC)N=C1C1=CC2=CC=CC=C2S1 ASCRLTIXZKFQJI-UHFFFAOYSA-N 0.000 claims description 4
- IQWQEVCQXDEINJ-UHFFFAOYSA-N 1-ethyl-3-[hydroxy(diphenyl)methyl]-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 IQWQEVCQXDEINJ-UHFFFAOYSA-N 0.000 claims description 4
- HCIKDGRDIWWCHS-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-3-[(2-methoxyphenyl)methyl]-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1OC HCIKDGRDIWWCHS-UHFFFAOYSA-N 0.000 claims description 4
- WNWRPVFIEUZBNY-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-[4-(3-phenylmethoxyprop-1-ynyl)phenyl]-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=C1)=CC=C1C#CCOCC1=CC=CC=C1 WNWRPVFIEUZBNY-UHFFFAOYSA-N 0.000 claims description 4
- PKLOQQDQBJEJQS-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-[(3-phenylphenyl)methyl]-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC(C=1)=CC=CC=1C1=CC=CC=C1 PKLOQQDQBJEJQS-UHFFFAOYSA-N 0.000 claims description 4
- DNVLRCDPCFXSAQ-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-[(4-phenylphenyl)methyl]-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC(C=C1)=CC=C1C1=CC=CC=C1 DNVLRCDPCFXSAQ-UHFFFAOYSA-N 0.000 claims description 4
- WQQPGMSAJNSWML-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-prop-2-ynyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(CC#C)C(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 WQQPGMSAJNSWML-UHFFFAOYSA-N 0.000 claims description 4
- MAGIXZPMCBHOFV-UHFFFAOYSA-N 2-(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)acetamide Chemical compound N=1C(CC(N)=O)C(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 MAGIXZPMCBHOFV-UHFFFAOYSA-N 0.000 claims description 4
- CSBZWVNBMFQYTQ-UHFFFAOYSA-N 3,5-dibenzyl-7,8-dimethoxy-1-phenyl-5h-2,3-benzodiazepin-4-one Chemical compound O=C1N(CC=2C=CC=CC=2)N=C(C=2C=CC=CC=2)C=2C=C(OC)C(OC)=CC=2C1CC1=CC=CC=C1 CSBZWVNBMFQYTQ-UHFFFAOYSA-N 0.000 claims description 4
- ZEKZWMAZSZKUMS-UHFFFAOYSA-N 3-(1-benzyl-4-hydroxypiperidin-4-yl)-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(CC1)(O)CCN1CC1=CC=CC=C1 ZEKZWMAZSZKUMS-UHFFFAOYSA-N 0.000 claims description 4
- XMVVYXKYZQBPRB-UHFFFAOYSA-N 3-[(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)methyl]benzamide Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(C(N)=O)=C1 XMVVYXKYZQBPRB-UHFFFAOYSA-N 0.000 claims description 4
- MBUSWDJSEGOHES-UHFFFAOYSA-N 3-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)methyl]benzamide Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(C)C(=O)C1CC1=CC=CC(C(N)=O)=C1 MBUSWDJSEGOHES-UHFFFAOYSA-N 0.000 claims description 4
- FGMBQTNFQLFNRR-UHFFFAOYSA-N 3-[1,2-bis(4-bromophenyl)ethyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(C=1C=CC(Br)=CC=1)CC1=CC=C(Br)C=C1 FGMBQTNFQLFNRR-UHFFFAOYSA-N 0.000 claims description 4
- ZOKLVYBIKSORDC-UHFFFAOYSA-N 5-(2-bromophenyl)-7,8-dimethoxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=CC=C1Br ZOKLVYBIKSORDC-UHFFFAOYSA-N 0.000 claims description 4
- AALFNMGUYPJUST-UHFFFAOYSA-N 5-[3,5-bis(trifluoromethyl)phenyl]-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 AALFNMGUYPJUST-UHFFFAOYSA-N 0.000 claims description 4
- XLAQCBYTYMNGDR-UHFFFAOYSA-N 7,8-dimethoxy-1-phenyl-3-propyl-5h-2,3-benzodiazepin-4-one Chemical compound C12=CC(OC)=C(OC)C=C2CC(=O)N(CCC)N=C1C1=CC=CC=C1 XLAQCBYTYMNGDR-UHFFFAOYSA-N 0.000 claims description 4
- FVCLLYSNQRDQGL-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(C)N=C1C1=CC=CC=C1 FVCLLYSNQRDQGL-UHFFFAOYSA-N 0.000 claims description 4
- GVWCSZJBGUTVJA-UHFFFAOYSA-N 8-methoxy-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C=1C(OC)=CC=C2C=1N(C)C(=O)CN=C2C1=CC=CC=C1 GVWCSZJBGUTVJA-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- IRSNKBQBTFWNAN-UHFFFAOYSA-N ethyl 2-(7,8-diethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-1-yl)acetate Chemical compound N=1CC(=O)N(CC(=O)OCC)C2=CC(OCC)=C(OCC)C=C2C=1C1=CC=CC=C1 IRSNKBQBTFWNAN-UHFFFAOYSA-N 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 claims description 3
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 230000007170 pathology Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 150000002429 hydrazines Chemical class 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000002524 organometallic group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- LWODOYULCBDJNI-UHFFFAOYSA-N 3-[[2-(aminomethyl)phenyl]methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3H-1,4-benzodiazepin-2-one N-[[2-(7,8-dimethoxy-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)phenyl]methyl]acetamide Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1CN.C1=2C=C(OC)C(OC)=CC=2NC(=O)C(C=2C(=CC=CC=2)CNC(C)=O)N=C1C1=CC=CC=C1 LWODOYULCBDJNI-UHFFFAOYSA-N 0.000 claims 1
- RGEJQYAPVPRMKI-UHFFFAOYSA-N 3-benzyl-8-ethoxy-1-ethyl-7-methoxy-5-phenyl-3h-1,4-benzodiazepin-2-one;8-ethoxy-1-ethyl-7-methoxy-3,5-diphenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OCC)=CC=2N(CC)C(=O)C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1.N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(CC)C(=O)C1CC1=CC=CC=C1 RGEJQYAPVPRMKI-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- NSFKQWZKLQUICF-UHFFFAOYSA-N 7,8-dimethoxy-3-(2-methylsulfanylethyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one;3-(1h-indol-3-ylmethyl)-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CCSC)N=C1C1=CC=CC=C1.C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CC=2C3=CC=CC=C3NC=2)N=C1C1=CC=CC=C1 NSFKQWZKLQUICF-UHFFFAOYSA-N 0.000 claims 1
- ICYHWTLVAMZICW-UHFFFAOYSA-N 8-bromo-5-(4-bromophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one 7-iodo-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound IC=1C=CC2=C(C(=NCC(N2)=O)C2=CC(=CC=C2)C(F)(F)F)C1.BrC1=CC2=C(C(=NCC(N2)=O)C2=CC=C(C=C2)Br)C=C1 ICYHWTLVAMZICW-UHFFFAOYSA-N 0.000 claims 1
- WHPSIXNYRRDLLR-UHFFFAOYSA-N BrC1=CC=C(C=C1)C1=NCC(NC2=C1C=C(C(=C2)OC)OC)=O.BrC2=CC=C(C=C2)C2=NCC(N(C1=C2C=C(C(=C1)OC)OC)C)=O Chemical compound BrC1=CC=C(C=C1)C1=NCC(NC2=C1C=C(C(=C2)OC)OC)=O.BrC2=CC=C(C=C2)C2=NCC(N(C1=C2C=C(C(=C1)OC)OC)C)=O WHPSIXNYRRDLLR-UHFFFAOYSA-N 0.000 claims 1
- XWIOUMQHEOMYLF-UHFFFAOYSA-N C(C)N1C(C(N=C(C2=C1C=C(C(=C2)OC)OC)C2=CC=CC=C2)CC2=CC(=CC=C2)C(F)(F)F)=O.C(C)OC2=CC1=C(C(=NCC(N1C)=O)C1=CC=CC=C1)C=C2OC Chemical compound C(C)N1C(C(N=C(C2=C1C=C(C(=C2)OC)OC)C2=CC=CC=C2)CC2=CC(=CC=C2)C(F)(F)F)=O.C(C)OC2=CC1=C(C(=NCC(N1C)=O)C1=CC=CC=C1)C=C2OC XWIOUMQHEOMYLF-UHFFFAOYSA-N 0.000 claims 1
- XMOWNHARCXKXBD-UHFFFAOYSA-N C(C)N1N=C(C2=C(CC1=O)C=C(C(=C2)OC)OC)C2=CC=CC=C2.COC=2C(=CC1=C(CC(N(N=C1C1=CC=CC=C1)CCCCCCCCCCCC(=O)OC)=O)C2)OC Chemical compound C(C)N1N=C(C2=C(CC1=O)C=C(C(=C2)OC)OC)C2=CC=CC=C2.COC=2C(=CC1=C(CC(N(N=C1C1=CC=CC=C1)CCCCCCCCCCCC(=O)OC)=O)C2)OC XMOWNHARCXKXBD-UHFFFAOYSA-N 0.000 claims 1
- CACJYBKRXKLING-UHFFFAOYSA-N C(C)OC1=CC2=C(C(=NCC(N2)=O)C2=CC=CC=C2)C=C1OC.C(C)N1C(C(N=C(C2=C1C=C(C(=C2)OC)OC)C2=CC=CC=C2)CC2=C(C=CC=C2)C)=O Chemical compound C(C)OC1=CC2=C(C(=NCC(N2)=O)C2=CC=CC=C2)C=C1OC.C(C)N1C(C(N=C(C2=C1C=C(C(=C2)OC)OC)C2=CC=CC=C2)CC2=C(C=CC=C2)C)=O CACJYBKRXKLING-UHFFFAOYSA-N 0.000 claims 1
- MSXQQBHAMHZOSF-UHFFFAOYSA-N C(C)OC=1C(=CC2=C(C(=NCC(N2)=O)C2=CC=CC=C2)C1)OCC.C(C1=CC=CC=C1)N1C(CN=C(C2=C1C=C(C(=C2)OC)OC)C2=CC=CC=C2)=O Chemical compound C(C)OC=1C(=CC2=C(C(=NCC(N2)=O)C2=CC=CC=C2)C1)OCC.C(C1=CC=CC=C1)N1C(CN=C(C2=C1C=C(C(=C2)OC)OC)C2=CC=CC=C2)=O MSXQQBHAMHZOSF-UHFFFAOYSA-N 0.000 claims 1
- GJBQXRBJGJSZGQ-UHFFFAOYSA-N C(C)OC=1C(=CC2=C(C(=NCC(N2CC)=O)C2=CC=CC=C2)C1)OCC.C(C)OC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=CC=C2)C1)OCC Chemical compound C(C)OC=1C(=CC2=C(C(=NCC(N2CC)=O)C2=CC=CC=C2)C1)OCC.C(C)OC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=CC=C2)C1)OCC GJBQXRBJGJSZGQ-UHFFFAOYSA-N 0.000 claims 1
- RGZATWPGZGJBNA-UHFFFAOYSA-N C(C1=CC=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OC)OC)=O.COC=2C(=CC1=C(C(=NC(C(N1)=O)CC(C)C)C1=CC=CC=C1)C2)OC Chemical compound C(C1=CC=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OC)OC)=O.COC=2C(=CC1=C(C(=NC(C(N1)=O)CC(C)C)C1=CC=CC=C1)C2)OC RGZATWPGZGJBNA-UHFFFAOYSA-N 0.000 claims 1
- ALCIOTMJXMIVGN-UHFFFAOYSA-N C(C1=CC=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OCC)OC)=O.C2(=CC=CC=C2)C2C(NC1=C(C(=N2)C2=CC=CC=C2)C=C(C(=C1)OCC)OC)=O Chemical compound C(C1=CC=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OCC)OC)=O.C2(=CC=CC=C2)C2C(NC1=C(C(=N2)C2=CC=CC=C2)C=C(C(=C1)OCC)OC)=O ALCIOTMJXMIVGN-UHFFFAOYSA-N 0.000 claims 1
- RPVYXBPOHVAWDH-UHFFFAOYSA-N C(C1=CC=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OCC)OCC)=O.C(C)OC=2C(=CC1=C(C(=NC(C(N1)=O)C)C1=CC=CC=C1)C2)OCC Chemical compound C(C1=CC=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OCC)OCC)=O.C(C)OC=2C(=CC1=C(C(=NC(C(N1)=O)C)C1=CC=CC=C1)C2)OCC RPVYXBPOHVAWDH-UHFFFAOYSA-N 0.000 claims 1
- KKSCPPRBRLHOCT-UHFFFAOYSA-N C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=CC1)C1=NCC(N(C2=C1C=C(C(=C2)OC)OC)C)=O.N2C=CC1=CC(=CC=C21)C2=NCC(N(C1=C2C=C(C(=C1)OC)OC)C)=O Chemical compound C(C1=CC=CC=C1)OC=1C=C2C=CC(=CC2=CC1)C1=NCC(N(C2=C1C=C(C(=C2)OC)OC)C)=O.N2C=CC1=CC(=CC=C21)C2=NCC(N(C1=C2C=C(C(=C1)OC)OC)C)=O KKSCPPRBRLHOCT-UHFFFAOYSA-N 0.000 claims 1
- LDTSFQUCNKOGRA-UHUPAWRPSA-N C(C1=CC=CC=C1)[C@H]1C(N(C2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OC)OC)C)=O.C(C2=CC=CC=C2)[C@H]2C(NC1=C(C(=N2)C2=CC=CC=C2)C=C(C(=C1)OC)OC)=O Chemical compound C(C1=CC=CC=C1)[C@H]1C(N(C2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OC)OC)C)=O.C(C2=CC=CC=C2)[C@H]2C(NC1=C(C(=N2)C2=CC=CC=C2)C=C(C(=C1)OC)OC)=O LDTSFQUCNKOGRA-UHUPAWRPSA-N 0.000 claims 1
- QKQRIOHJVJKXJJ-UHFFFAOYSA-N COC=1C(=CC2=C(C(=NC(C(N2)=O)C2=CC=CC=C2)C2=CC=CC=C2)C1)OC.CCC(=O)NCC1=C(C=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OC)OC)=O Chemical compound COC=1C(=CC2=C(C(=NC(C(N2)=O)C2=CC=CC=C2)C2=CC=CC=C2)C1)OC.CCC(=O)NCC1=C(C=CC=C1)C1C(NC2=C(C(=N1)C1=CC=CC=C1)C=C(C(=C2)OC)OC)=O QKQRIOHJVJKXJJ-UHFFFAOYSA-N 0.000 claims 1
- BVJHNHRFUUTGBH-UHFFFAOYSA-N COC=1C(=CC2=C(C(=NCC(N2)=O)C2=CC=CC=C2)C1)OC.COC=1C=CC2=C(C(=NCC(N2)=O)C2=CC(=CC=C2)C(F)(F)F)C1 Chemical compound COC=1C(=CC2=C(C(=NCC(N2)=O)C2=CC=CC=C2)C1)OC.COC=1C=CC2=C(C(=NCC(N2)=O)C2=CC(=CC=C2)C(F)(F)F)C1 BVJHNHRFUUTGBH-UHFFFAOYSA-N 0.000 claims 1
- MIRKNYSWZBBCFK-RRABGKBLSA-N COC=1C(=CC2=C(C(=NCC(N2C)=O)C#CC2=CC=CC=C2)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)\C=C\C2=CC=CC=C2)C1)OC Chemical compound COC=1C(=CC2=C(C(=NCC(N2C)=O)C#CC2=CC=CC=C2)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)\C=C\C2=CC=CC=C2)C1)OC MIRKNYSWZBBCFK-RRABGKBLSA-N 0.000 claims 1
- MUHQOPNLBFXZIS-UHFFFAOYSA-N COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=C(C=CC=C2)C)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)N2CCCCC2)C1)OC Chemical compound COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=C(C=CC=C2)C)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)N2CCCCC2)C1)OC MUHQOPNLBFXZIS-UHFFFAOYSA-N 0.000 claims 1
- KRIVIONWBCTWRS-UHFFFAOYSA-N COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC(=C(C=C2)OC)OC)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=CC=C2)C1)OC Chemical compound COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC(=C(C=C2)OC)OC)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=CC=C2)C1)OC KRIVIONWBCTWRS-UHFFFAOYSA-N 0.000 claims 1
- HKSKRDCCGFZXFW-UHFFFAOYSA-N COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=NC=C2)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=C(C=C2)F)C1)OC Chemical compound COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=NC=C2)C1)OC.COC=1C(=CC2=C(C(=NCC(N2C)=O)C2=CC=C(C=C2)F)C1)OC HKSKRDCCGFZXFW-UHFFFAOYSA-N 0.000 claims 1
- RAWRLRIBHDQFCL-UHFFFAOYSA-N COC=1C(=CC2=C(CC(N(N=C2C2=CC=C(C=C2)C2=CC(=CC=C2)OC)C)=O)C1)OC.COC=1C(=CC2=C(CC(N(N=C2C2=CC=C(C=C2)C2=C(C=CC=C2)OC)C)=O)C1)OC Chemical compound COC=1C(=CC2=C(CC(N(N=C2C2=CC=C(C=C2)C2=CC(=CC=C2)OC)C)=O)C1)OC.COC=1C(=CC2=C(CC(N(N=C2C2=CC=C(C=C2)C2=C(C=CC=C2)OC)C)=O)C1)OC RAWRLRIBHDQFCL-UHFFFAOYSA-N 0.000 claims 1
- AGPDUKNQLNXZAI-UHFFFAOYSA-N ClC1=C(CC2C(N(C3=C(C(=N2)C2=CC=CC=C2)C=C(C(=C3)OC)OC)CC)=O)C=C(C=C1)Cl.ClC1=C(CC3C(N(C2=C(C(=N3)C3=CC=CC=C3)C=C(C(=C2)OC)OC)CC)=O)C=CC(=C1)Cl Chemical compound ClC1=C(CC2C(N(C3=C(C(=N2)C2=CC=CC=C2)C=C(C(=C3)OC)OC)CC)=O)C=C(C=C1)Cl.ClC1=C(CC3C(N(C2=C(C(=N3)C3=CC=CC=C3)C=C(C(=C2)OC)OC)CC)=O)C=CC(=C1)Cl AGPDUKNQLNXZAI-UHFFFAOYSA-N 0.000 claims 1
- XPCPMRHERAWHIA-UHFFFAOYSA-N ClC1=CC=C(C=C1)C1=NN(C(CC2=C1C=C(C(=C2)OC)OC)=O)C.COC=2C(=CC1=C(CC(N(N=C1C1=CC3=CC=CC=C3C=C1)C)=O)C2)OC Chemical compound ClC1=CC=C(C=C1)C1=NN(C(CC2=C1C=C(C(=C2)OC)OC)=O)C.COC=2C(=CC1=C(CC(N(N=C1C1=CC3=CC=CC=C3C=C1)C)=O)C2)OC XPCPMRHERAWHIA-UHFFFAOYSA-N 0.000 claims 1
- BUMYJRWOEZGKML-UHFFFAOYSA-N N1C(=CC2=CC=CC=C12)C1=NCC(N(C2=C1C=C(C(=C2)OC)OC)C)=O.COC=2C(=CC1=C(C(=NCC(N1C)=O)C1=CC3=CC=C(C=C3C=C1)OC)C2)OC Chemical compound N1C(=CC2=CC=CC=C12)C1=NCC(N(C2=C1C=C(C(=C2)OC)OC)C)=O.COC=2C(=CC1=C(C(=NCC(N1C)=O)C1=CC3=CC=C(C=C3C=C1)OC)C2)OC BUMYJRWOEZGKML-UHFFFAOYSA-N 0.000 claims 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract description 5
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract description 5
- 239000000543 intermediate Substances 0.000 abstract description 5
- 125000004122 cyclic group Chemical group 0.000 abstract description 3
- ZHYMGSPDEVXULU-UHFFFAOYSA-N 1,2-benzodiazepin-3-one Chemical class N1=NC(=O)C=CC2=CC=CC=C21 ZHYMGSPDEVXULU-UHFFFAOYSA-N 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 175
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 78
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 50
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 45
- 238000004587 chromatography analysis Methods 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- IHVGHQMSDGPLJE-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-3-[(2-nitrophenyl)methyl]-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1[N+]([O-])=O IHVGHQMSDGPLJE-UHFFFAOYSA-N 0.000 description 30
- HXBMIQJOSHZCFX-UHFFFAOYSA-N 1-(bromomethyl)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1CBr HXBMIQJOSHZCFX-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 239000012298 atmosphere Substances 0.000 description 25
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 24
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 24
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000000377 silicon dioxide Substances 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- WNMYELHTHAILAM-UHFFFAOYSA-N (2-amino-4,5-dimethoxyphenyl)-phenylmethanone Chemical compound C1=C(OC)C(OC)=CC(N)=C1C(=O)C1=CC=CC=C1 WNMYELHTHAILAM-UHFFFAOYSA-N 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 17
- VGESKMFUGWXWCQ-UHFFFAOYSA-N 5-(4-bromophenyl)-7,8-dimethoxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=C(Br)C=C1 VGESKMFUGWXWCQ-UHFFFAOYSA-N 0.000 description 17
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 17
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 17
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- GIUTUZDGHNZVIA-UHFFFAOYSA-N 2-(ethylamino)acetic acid;hydrochloride Chemical compound Cl.CCNCC(O)=O GIUTUZDGHNZVIA-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- UDLAUVFRZXIQJS-UHFFFAOYSA-N 1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1C(=O)CN=CC2=CC=CC=C21 UDLAUVFRZXIQJS-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 10
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 9
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 8
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- KBQFSUZPDHZXDF-UHFFFAOYSA-N (2-amino-4,5-diethoxyphenyl)-phenylmethanone Chemical compound C1=C(OCC)C(OCC)=CC(N)=C1C(=O)C1=CC=CC=C1 KBQFSUZPDHZXDF-UHFFFAOYSA-N 0.000 description 7
- NNNYJKWZQDHNLB-UHFFFAOYSA-N 5-(4-bromophenyl)-1-ethyl-7,8-dimethoxy-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=C(Br)C=C1 NNNYJKWZQDHNLB-UHFFFAOYSA-N 0.000 description 7
- DFIUPVPLSDQFHP-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-2,5-dihydro-2,3-benzodiazepine-1,4-dione Chemical compound C1C(=O)N(C)NC(=O)C2=C1C=C(OC)C(OC)=C2 DFIUPVPLSDQFHP-UHFFFAOYSA-N 0.000 description 7
- JPTWVKXRRJCVIB-UHFFFAOYSA-N 7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=CC=C1 JPTWVKXRRJCVIB-UHFFFAOYSA-N 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 229940095074 cyclic amp Drugs 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- GZHJMAVOLIEASV-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2CC(=O)NN=C1C1=CC2=CC=CC=C2S1 GZHJMAVOLIEASV-UHFFFAOYSA-N 0.000 description 6
- GYYOUAWPCTYJIG-UHFFFAOYSA-N 2-(2-hydrazinyl-2-oxoethyl)-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(CC(=O)NN)=C(C(O)=O)C=C1OC GYYOUAWPCTYJIG-UHFFFAOYSA-N 0.000 description 6
- MOLLMKZLHNWYJJ-UHFFFAOYSA-N 3-[(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)methyl]benzonitrile Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(C#N)=C1 MOLLMKZLHNWYJJ-UHFFFAOYSA-N 0.000 description 6
- IQAKUMDPJRAVIK-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=C(Cl)C=C1 IQAKUMDPJRAVIK-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- IZQZWZCYWZVNLM-UHFFFAOYSA-N (2-amino-4-ethoxy-5-methoxyphenyl)-phenylmethanone Chemical compound C1=C(OC)C(OCC)=CC(N)=C1C(=O)C1=CC=CC=C1 IZQZWZCYWZVNLM-UHFFFAOYSA-N 0.000 description 5
- ZWVMLYRJXORSEP-LURJTMIESA-N (2s)-hexane-1,2,6-triol Chemical compound OCCCC[C@H](O)CO ZWVMLYRJXORSEP-LURJTMIESA-N 0.000 description 5
- UDCXBAXTPRFWEW-INIZCTEOSA-N (3s)-3-(4-aminobutyl)-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@@H](CCCCN)C(=O)NC=1C=C(C(=CC=11)OC)OC)=C1C1=CC=CC=C1 UDCXBAXTPRFWEW-INIZCTEOSA-N 0.000 description 5
- QIYGTBUSLLNPAQ-UHFFFAOYSA-N 1-(4-iodophenyl)-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C1=CC=C(I)C=C1 QIYGTBUSLLNPAQ-UHFFFAOYSA-N 0.000 description 5
- DPZCMNIHVJZAFB-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 DPZCMNIHVJZAFB-UHFFFAOYSA-N 0.000 description 5
- NOUUHGZLGUYQON-UHFFFAOYSA-N 2-(carboxymethyl)-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(CC(O)=O)=C(C(O)=O)C=C1OC NOUUHGZLGUYQON-UHFFFAOYSA-N 0.000 description 5
- FFRMJYMNIWFUCU-UHFFFAOYSA-N 2-[(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)methyl]benzonitrile Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1C#N FFRMJYMNIWFUCU-UHFFFAOYSA-N 0.000 description 5
- HFVCJTKFVFFUPZ-UHFFFAOYSA-N 3-[(2-aminophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1N HFVCJTKFVFFUPZ-UHFFFAOYSA-N 0.000 description 5
- GHXSUOZEPFBJNH-UHFFFAOYSA-N 3-[(4-bromophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=C(Br)C=C1 GHXSUOZEPFBJNH-UHFFFAOYSA-N 0.000 description 5
- METKHLFZKUXAPB-UHFFFAOYSA-N 5-(3-bromophenyl)-1-ethyl-7,8-dimethoxy-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC(Br)=C1 METKHLFZKUXAPB-UHFFFAOYSA-N 0.000 description 5
- XEZRPKWKRMROBK-UHFFFAOYSA-N 6,7-dimethoxy-1,4-dihydroisochromen-3-one Chemical compound C1OC(=O)CC2=C1C=C(OC)C(OC)=C2 XEZRPKWKRMROBK-UHFFFAOYSA-N 0.000 description 5
- RLBVNENZMLRKLR-UHFFFAOYSA-N 7,8-dimethoxy-3,5-dihydro-2h-2,3-benzodiazepine-1,4-dione Chemical compound C1C(=O)NNC(=O)C2=C1C=C(OC)C(OC)=C2 RLBVNENZMLRKLR-UHFFFAOYSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 5
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- IYPFLJOJKBPBDC-UHFFFAOYSA-N 3-[(3-bromophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(Br)=C1 IYPFLJOJKBPBDC-UHFFFAOYSA-N 0.000 description 4
- AFYOEJRCJMPOQK-UHFFFAOYSA-N 3-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(C)C(=O)C1CC1=CC=CC(C#N)=C1 AFYOEJRCJMPOQK-UHFFFAOYSA-N 0.000 description 4
- NXYWSJCICDUCEQ-UHFFFAOYSA-N 5-(3-bromophenyl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC(Br)=C1 NXYWSJCICDUCEQ-UHFFFAOYSA-N 0.000 description 4
- JAFBIGGLFRQXES-UHFFFAOYSA-N 7,8-diethoxy-1-ethyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2N(CC)C(=O)CN=C1C1=CC=CC=C1 JAFBIGGLFRQXES-UHFFFAOYSA-N 0.000 description 4
- QLVZFXHPKMZWMK-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-3,4-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound CN1C(=O)CNC(=O)C2=C1C=C(OC)C(OC)=C2 QLVZFXHPKMZWMK-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YFUREOKAZJCOMQ-UHFFFAOYSA-N (2-amino-5-iodophenyl)-[3-(trifluoromethyl)phenyl]methanone Chemical compound NC1=CC=C(I)C=C1C(=O)C1=CC=CC(C(F)(F)F)=C1 YFUREOKAZJCOMQ-UHFFFAOYSA-N 0.000 description 3
- DFWFNMPYVHZTMB-FQEVSTJZSA-N (3s)-3-benzyl-7,8-dimethoxy-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C([C@H]1C(=O)N(C)C=2C=C(C(=CC=2C(C=2C=CC=CC=2)=N1)OC)OC)C1=CC=CC=C1 DFWFNMPYVHZTMB-FQEVSTJZSA-N 0.000 description 3
- BBIXYYCWUHISQM-FQEVSTJZSA-N (3s)-3-benzyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C([C@H]1C(=O)NC=2C=C(C(=CC=2C(C=2C=CC=CC=2)=N1)OC)OC)C1=CC=CC=C1 BBIXYYCWUHISQM-FQEVSTJZSA-N 0.000 description 3
- DTYUTSMRCQYVNW-UHFFFAOYSA-N 1,2-diethoxy-4-nitrobenzene Chemical compound CCOC1=CC=C([N+]([O-])=O)C=C1OCC DTYUTSMRCQYVNW-UHFFFAOYSA-N 0.000 description 3
- UKHBRHXBBYAMKX-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-3-methyl-5-propyl-5h-2,3-benzodiazepin-4-one Chemical compound CN1C(=O)C(CCC)C2=CC(OCC)=C(OCC)C=C2C(C=2SC3=CC=CC=C3C=2)=N1 UKHBRHXBBYAMKX-UHFFFAOYSA-N 0.000 description 3
- RXKFGIJSAAGEOS-UHFFFAOYSA-N 1-(2-hydroxyethyl)-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(CCO)C(=O)CN=C1C1=CC=CC=C1 RXKFGIJSAAGEOS-UHFFFAOYSA-N 0.000 description 3
- RBWSNKAIGSTHNQ-UHFFFAOYSA-N 1-(4-bromophenyl)-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C1=CC=C(Br)C=C1 RBWSNKAIGSTHNQ-UHFFFAOYSA-N 0.000 description 3
- VQJSSLAQHFVHJH-UHFFFAOYSA-N 1-[4-(3-acetylphenyl)phenyl]-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC(C(C)=O)=C1 VQJSSLAQHFVHJH-UHFFFAOYSA-N 0.000 description 3
- ICARBYJHFKZIFD-UHFFFAOYSA-N 1-[4-(4-acetylphenyl)phenyl]-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=C(C(C)=O)C=C1 ICARBYJHFKZIFD-UHFFFAOYSA-N 0.000 description 3
- MIXIYVAEJDWEGL-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)phenyl]-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 MIXIYVAEJDWEGL-UHFFFAOYSA-N 0.000 description 3
- ZFBLKBAGSSRDAP-UHFFFAOYSA-N 1-[4-(furan-2-yl)phenyl]-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CO1 ZFBLKBAGSSRDAP-UHFFFAOYSA-N 0.000 description 3
- OWTKSBICDHTGEY-UHFFFAOYSA-N 1-[4-[3,5-bis(trifluoromethyl)phenyl]phenyl]-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OWTKSBICDHTGEY-UHFFFAOYSA-N 0.000 description 3
- HULIXCDYHMLUNC-UHFFFAOYSA-N 1-benzyl-7,8-diethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1CN=C(C=2C=CC=CC=2)C=2C=C(OCC)C(OCC)=CC=2N1CC1=CC=CC=C1 HULIXCDYHMLUNC-UHFFFAOYSA-N 0.000 description 3
- DBSPEUQZDHURPN-UHFFFAOYSA-N 1-benzyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1CN=C(C=2C=CC=CC=2)C=2C=C(OC)C(OC)=CC=2N1CC1=CC=CC=C1 DBSPEUQZDHURPN-UHFFFAOYSA-N 0.000 description 3
- OUWMQCZHCUEXLS-UHFFFAOYSA-N 1-ethyl-7,8-dihydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(O)=C(O)C=C2C=1C1=CC=CC=C1 OUWMQCZHCUEXLS-UHFFFAOYSA-N 0.000 description 3
- CYTYSYYPAYFDSR-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-3-[(2-methylphenyl)methyl]-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1C CYTYSYYPAYFDSR-UHFFFAOYSA-N 0.000 description 3
- BJFZFRGUSAEHBG-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-3-[(3-methoxyphenyl)methyl]-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(OC)=C1 BJFZFRGUSAEHBG-UHFFFAOYSA-N 0.000 description 3
- XEGSKHDKMYFPCD-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-3-[(4-methylphenyl)methyl]-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=C(C)C=C1 XEGSKHDKMYFPCD-UHFFFAOYSA-N 0.000 description 3
- WAXLSETXOXLXDV-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-(4-phenylphenyl)-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=C1)=CC=C1C1=CC=CC=C1 WAXLSETXOXLXDV-UHFFFAOYSA-N 0.000 description 3
- JIIPPKMAHMFTQN-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-[4-(2-phenylethyl)phenyl]-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=C1)=CC=C1CCC1=CC=CC=C1 JIIPPKMAHMFTQN-UHFFFAOYSA-N 0.000 description 3
- YNQKOAZCUZKWBE-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-[4-(2-phenylethynyl)phenyl]-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=C1)=CC=C1C#CC1=CC=CC=C1 YNQKOAZCUZKWBE-UHFFFAOYSA-N 0.000 description 3
- MLZWVOXBBIWEQR-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-phenyl-3-[[3-(trifluoromethyl)phenyl]methyl]-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(C(F)(F)F)=C1 MLZWVOXBBIWEQR-UHFFFAOYSA-N 0.000 description 3
- TXJUTRJFNRYTHH-UHFFFAOYSA-N 1h-3,1-benzoxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)NC2=C1 TXJUTRJFNRYTHH-UHFFFAOYSA-N 0.000 description 3
- GZKJVGPLYYUSTK-UHFFFAOYSA-N 2-(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)acetonitrile Chemical compound N=1C(CC#N)C(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 GZKJVGPLYYUSTK-UHFFFAOYSA-N 0.000 description 3
- ONANEURZGVLNCQ-UHFFFAOYSA-N 2-[(8-ethoxy-7-methoxy-1-methyl-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)methyl]benzonitrile Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(C)C(=O)C1CC1=CC=CC=C1C#N ONANEURZGVLNCQ-UHFFFAOYSA-N 0.000 description 3
- PAGHLFPRFADKFP-UHFFFAOYSA-N 2-ethoxy-1-methoxy-4-nitrobenzene Chemical compound CCOC1=CC([N+]([O-])=O)=CC=C1OC PAGHLFPRFADKFP-UHFFFAOYSA-N 0.000 description 3
- KQWHHDCWLCCRLQ-UHFFFAOYSA-N 3,4-dimethoxybenzyl acetate Chemical compound COC1=CC=C(COC(C)=O)C=C1OC KQWHHDCWLCCRLQ-UHFFFAOYSA-N 0.000 description 3
- ASJOGLHFOISWHA-UHFFFAOYSA-N 3-(1h-imidazol-5-ylmethyl)-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OC)=CC=2NC(=O)C1CC1=CNC=N1 ASJOGLHFOISWHA-UHFFFAOYSA-N 0.000 description 3
- WRVUNDXYONRSPO-UHFFFAOYSA-N 3-(1h-indol-3-ylmethyl)-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CC=2C3=CC=CC=C3NC=2)N=C1C1=CC=CC=C1 WRVUNDXYONRSPO-UHFFFAOYSA-N 0.000 description 3
- KPXOZBSLTVTKAJ-UHFFFAOYSA-N 3-(3-hydroxypropyl)-7,8-dimethoxy-1-phenyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(CCCO)N=C1C1=CC=CC=C1 KPXOZBSLTVTKAJ-UHFFFAOYSA-N 0.000 description 3
- NIIXULBXOKLVNO-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=C(Cl)C=C1Cl NIIXULBXOKLVNO-UHFFFAOYSA-N 0.000 description 3
- KAIVUBLYJNIMRK-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC(Cl)=CC=C1Cl KAIVUBLYJNIMRK-UHFFFAOYSA-N 0.000 description 3
- OHFLKROAUPNRAB-UHFFFAOYSA-N 3-[(2-bromophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1Br OHFLKROAUPNRAB-UHFFFAOYSA-N 0.000 description 3
- SJDHKJJWGILDIO-UHFFFAOYSA-N 3-[(2-chlorophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1Cl SJDHKJJWGILDIO-UHFFFAOYSA-N 0.000 description 3
- CGOMMLCWBCUVIU-UHFFFAOYSA-N 3-[(3,5-dibromophenyl)methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC(Br)=CC(Br)=C1 CGOMMLCWBCUVIU-UHFFFAOYSA-N 0.000 description 3
- MYUOCABMOOQGAE-UHFFFAOYSA-N 3-[(3-bromophenyl)-hydroxymethyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1C(O)C1=CC=CC(Br)=C1 MYUOCABMOOQGAE-UHFFFAOYSA-N 0.000 description 3
- HMGUXGCHAZNRKQ-UHFFFAOYSA-N 3-[[2-(aminomethyl)phenyl]methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1CN HMGUXGCHAZNRKQ-UHFFFAOYSA-N 0.000 description 3
- ZFYBWAVBGULGRO-UHFFFAOYSA-N 3-[[3-(aminomethyl)phenyl]methyl]-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC(CN)=C1 ZFYBWAVBGULGRO-UHFFFAOYSA-N 0.000 description 3
- RGGVIONSFAYEAU-UHFFFAOYSA-N 3-benzyl-1-ethyl-7,8-dimethoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C1N(CC)C2=CC(OC)=C(OC)C=C2C(C=2C=CC=CC=2)=NC1CC1=CC=CC=C1 RGGVIONSFAYEAU-UHFFFAOYSA-N 0.000 description 3
- FJLGAECREVUWAB-UHFFFAOYSA-N 3-benzyl-7,8-diethoxy-1-ethyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OCC)C(OCC)=CC=2N(CC)C(=O)C1CC1=CC=CC=C1 FJLGAECREVUWAB-UHFFFAOYSA-N 0.000 description 3
- USUFZAYMDBWDIX-UHFFFAOYSA-N 3-benzyl-7,8-diethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OCC)C(OCC)=CC=2NC(=O)C1CC1=CC=CC=C1 USUFZAYMDBWDIX-UHFFFAOYSA-N 0.000 description 3
- LIDAPGJWNNLPST-UHFFFAOYSA-N 3-benzyl-7,8-dimethoxy-1-phenyl-5h-2,3-benzodiazepin-4-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OC)=CC=2CC(=O)N1CC1=CC=CC=C1 LIDAPGJWNNLPST-UHFFFAOYSA-N 0.000 description 3
- BBIXYYCWUHISQM-UHFFFAOYSA-N 3-benzyl-7,8-dimethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OC)=CC=2NC(=O)C1CC1=CC=CC=C1 BBIXYYCWUHISQM-UHFFFAOYSA-N 0.000 description 3
- ZIDNWYSLKVVCCR-UHFFFAOYSA-N 3-benzyl-8-ethoxy-1-ethyl-7-methoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2N(CC)C(=O)C1CC1=CC=CC=C1 ZIDNWYSLKVVCCR-UHFFFAOYSA-N 0.000 description 3
- BWIFWMKTQKKQAD-UHFFFAOYSA-N 3-benzyl-8-ethoxy-7-methoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N1=C(C=2C=CC=CC=2)C=2C=C(OC)C(OCC)=CC=2NC(=O)C1CC1=CC=CC=C1 BWIFWMKTQKKQAD-UHFFFAOYSA-N 0.000 description 3
- DHPLXTWXNFZRNP-UHFFFAOYSA-N 3-dodecyl-7,8-dimethoxy-1-phenyl-5h-2,3-benzodiazepin-4-one Chemical compound C12=CC(OC)=C(OC)C=C2CC(=O)N(CCCCCCCCCCCC)N=C1C1=CC=CC=C1 DHPLXTWXNFZRNP-UHFFFAOYSA-N 0.000 description 3
- JEKQFQAZBUJHAU-UHFFFAOYSA-N 3-ethyl-7,8-dimethoxy-1-phenyl-5h-2,3-benzodiazepin-4-one Chemical compound C12=CC(OC)=C(OC)C=C2CC(=O)N(CC)N=C1C1=CC=CC=C1 JEKQFQAZBUJHAU-UHFFFAOYSA-N 0.000 description 3
- MSNOOZDMPWOJAH-UHFFFAOYSA-N 5-(1h-indol-2-yl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC2=CC=CC=C2N1 MSNOOZDMPWOJAH-UHFFFAOYSA-N 0.000 description 3
- IXVZTSJPZJXQPY-UHFFFAOYSA-N 5-(1h-indol-5-yl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=C(NC=C2)C2=C1 IXVZTSJPZJXQPY-UHFFFAOYSA-N 0.000 description 3
- CDFUJPZXXWWWOA-UHFFFAOYSA-N 5-(3,4-dimethoxyphenyl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=NCC(=O)N(C)C2=CC(OC)=C(OC)C=C12 CDFUJPZXXWWWOA-UHFFFAOYSA-N 0.000 description 3
- OUPKYSJIOYLADC-UHFFFAOYSA-N 5-(3-bromophenyl)-7,8-dimethoxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)CN=C1C1=CC=CC(Br)=C1 OUPKYSJIOYLADC-UHFFFAOYSA-N 0.000 description 3
- ONHNOXFEIIWTCK-UHFFFAOYSA-N 5-(4-acetylphenyl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=C(C(C)=O)C=C1 ONHNOXFEIIWTCK-UHFFFAOYSA-N 0.000 description 3
- KDLPXRWGSXHDDB-UHFFFAOYSA-N 5-(4-bromophenyl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=C(Br)C=C1 KDLPXRWGSXHDDB-UHFFFAOYSA-N 0.000 description 3
- HAOKXTLRQQFEST-UHFFFAOYSA-N 5-(4-fluorophenyl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=C(F)C=C1 HAOKXTLRQQFEST-UHFFFAOYSA-N 0.000 description 3
- ZRSAERBPVHGIPW-UHFFFAOYSA-N 5-(furan-2-yl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CO1 ZRSAERBPVHGIPW-UHFFFAOYSA-N 0.000 description 3
- HPQLFKGFLKDIAT-UHFFFAOYSA-N 5-chloro-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound CN1C(=O)CN=C(Cl)C2=C1C=C(OC)C(OC)=C2 HPQLFKGFLKDIAT-UHFFFAOYSA-N 0.000 description 3
- NALNPEFGPDBRCS-UHFFFAOYSA-N 7,8-diethoxy-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2N(C)C(=O)CN=C1C1=CC=CC=C1 NALNPEFGPDBRCS-UHFFFAOYSA-N 0.000 description 3
- UMPZEODMQVWKCC-UHFFFAOYSA-N 7,8-diethoxy-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2NC(=O)C(C)N=C1C1=CC=CC=C1 UMPZEODMQVWKCC-UHFFFAOYSA-N 0.000 description 3
- RBIMGKPHNCHXMS-UHFFFAOYSA-N 7,8-diethoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2NC(=O)CN=C1C1=CC=CC=C1 RBIMGKPHNCHXMS-UHFFFAOYSA-N 0.000 description 3
- LRICTWOHSPBXLD-UHFFFAOYSA-N 7,8-dimethoxy-1-[4-(2-methoxyphenyl)phenyl]-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC=C1OC LRICTWOHSPBXLD-UHFFFAOYSA-N 0.000 description 3
- IWMABSNJKZRWFO-UHFFFAOYSA-N 7,8-dimethoxy-1-[4-(3-methoxyphenyl)phenyl]-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound COC1=CC=CC(C=2C=CC(=CC=2)C=2C3=CC(OC)=C(OC)C=C3CC(=O)N(C)N=2)=C1 IWMABSNJKZRWFO-UHFFFAOYSA-N 0.000 description 3
- JEFSPAVNHMTXPS-UHFFFAOYSA-N 7,8-dimethoxy-1-[4-(4-methoxyphenyl)phenyl]-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C=2C3=CC(OC)=C(OC)C=C3CC(=O)N(C)N=2)C=C1 JEFSPAVNHMTXPS-UHFFFAOYSA-N 0.000 description 3
- LTCMYALFHUJZML-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-(2-methylphenyl)-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC=C1C LTCMYALFHUJZML-UHFFFAOYSA-N 0.000 description 3
- TVYHGRSGZGTTLT-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-(2-phenylethyl)-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1CCC1=CC=CC=C1 TVYHGRSGZGTTLT-UHFFFAOYSA-N 0.000 description 3
- WRCGPPOUYKGAFN-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-(3-phenylphenyl)-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C(C=1)=CC=CC=1C1=CC=CC=C1 WRCGPPOUYKGAFN-UHFFFAOYSA-N 0.000 description 3
- FZQNVHBWKUYPMO-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-(6-phenylmethoxynaphthalen-2-yl)-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C(C=C1C=C2)=CC=C1C=C2OCC1=CC=CC=C1 FZQNVHBWKUYPMO-UHFFFAOYSA-N 0.000 description 3
- QNTRIAZKHXMTKW-MDZDMXLPSA-N 7,8-dimethoxy-1-methyl-5-[(e)-2-phenylethenyl]-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1\C=C\C1=CC=CC=C1 QNTRIAZKHXMTKW-MDZDMXLPSA-N 0.000 description 3
- UHYVPWDNMXWRNH-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC=C1 UHYVPWDNMXWRNH-UHFFFAOYSA-N 0.000 description 3
- XRGUXDBXZXGOMC-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-piperidin-1-yl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1N1CCCCC1 XRGUXDBXZXGOMC-UHFFFAOYSA-N 0.000 description 3
- ZYNNEDGJJJTFMD-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-pyridin-4-yl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=NC=C1 ZYNNEDGJJJTFMD-UHFFFAOYSA-N 0.000 description 3
- GUDIDXQLBMNOSC-UHFFFAOYSA-N 7,8-dimethoxy-3,5-diphenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 GUDIDXQLBMNOSC-UHFFFAOYSA-N 0.000 description 3
- BRMKLBBTWJKINP-UHFFFAOYSA-N 7,8-dimethoxy-3-(2-methylpropyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CC(C)C)N=C1C1=CC=CC=C1 BRMKLBBTWJKINP-UHFFFAOYSA-N 0.000 description 3
- INRWZZJCVLANKR-UHFFFAOYSA-N 7,8-dimethoxy-3-(2-methylsulfanylethyl)-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(CCSC)N=C1C1=CC=CC=C1 INRWZZJCVLANKR-UHFFFAOYSA-N 0.000 description 3
- CBZDWXSMWJWFGA-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-(4-thiophen-2-ylphenyl)-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CS1 CBZDWXSMWJWFGA-UHFFFAOYSA-N 0.000 description 3
- DMPHKSRLDAUROB-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-(2-methylphenyl)phenyl]-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC=C1C DMPHKSRLDAUROB-UHFFFAOYSA-N 0.000 description 3
- XKJBVKQYRHXRAS-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-(3-methylphenyl)phenyl]-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC(C)=C1 XKJBVKQYRHXRAS-UHFFFAOYSA-N 0.000 description 3
- UJSOHZFFVQFFQG-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-(3-nitrophenyl)phenyl]-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC([N+]([O-])=O)=C1 UJSOHZFFVQFFQG-UHFFFAOYSA-N 0.000 description 3
- CCEIGWZSQJRJEM-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-(4-methylphenyl)phenyl]-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=C(C)C=C1 CCEIGWZSQJRJEM-UHFFFAOYSA-N 0.000 description 3
- ACXGWEHMIUPNGX-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-[4-[3-(trifluoromethyl)phenyl]phenyl]-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC(C(F)(F)F)=C1 ACXGWEHMIUPNGX-UHFFFAOYSA-N 0.000 description 3
- QTGCBGWMWURTNG-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-naphthalen-1-yl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C1=CC=CC2=CC=CC=C12 QTGCBGWMWURTNG-UHFFFAOYSA-N 0.000 description 3
- NDGQQCWWACOEMD-UHFFFAOYSA-N 7,8-dimethoxy-5-(2-methoxyphenyl)-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CC=C1OC NDGQQCWWACOEMD-UHFFFAOYSA-N 0.000 description 3
- URRSFRMIDFVNLG-UHFFFAOYSA-N 7,8-dimethoxy-5-(3-methoxyphenyl)-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound COC1=CC=CC(C=2C3=CC(OC)=C(OC)C=C3N(C)C(=O)CN=2)=C1 URRSFRMIDFVNLG-UHFFFAOYSA-N 0.000 description 3
- DUMABVVGUSIGPX-UHFFFAOYSA-N 7,8-dimethoxy-5-(4-methoxyphenyl)-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=CC(OC)=CC=C1C1=NCC(=O)N(C)C2=CC(OC)=C(OC)C=C12 DUMABVVGUSIGPX-UHFFFAOYSA-N 0.000 description 3
- DJQGTGLYMQOBAQ-UHFFFAOYSA-N 7,8-dimethoxy-5-(6-methoxynaphthalen-2-yl)-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1C(=O)N(C)C2=CC(OC)=C(OC)C=C2C(C2=CC3=CC=C(C=C3C=C2)OC)=N1 DJQGTGLYMQOBAQ-UHFFFAOYSA-N 0.000 description 3
- LUIUBCACSPXTPV-UHFFFAOYSA-N 7,8-dimethoxy-5-phenyl-1-propyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CCC)C2=CC(OC)=C(OC)C=C2C=1C1=CC=CC=C1 LUIUBCACSPXTPV-UHFFFAOYSA-N 0.000 description 3
- PICWHVLACPHMEF-UHFFFAOYSA-N 7-ethoxy-8-methoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=C(OC)C(OCC)=CC2=C1NC(=O)CN=C2C1=CC=CC=C1 PICWHVLACPHMEF-UHFFFAOYSA-N 0.000 description 3
- HSVRJODMAZOURU-UHFFFAOYSA-N 7-iodo-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound FC(F)(F)C1=CC=CC(C=2C3=CC(I)=CC=C3NC(=O)CN=2)=C1 HSVRJODMAZOURU-UHFFFAOYSA-N 0.000 description 3
- DDEUQSKXBUAGMW-UHFFFAOYSA-N 7-methoxy-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C12=CC(OC)=CC=C2N(C)C(=O)CN=C1C1=CC=CC=C1 DDEUQSKXBUAGMW-UHFFFAOYSA-N 0.000 description 3
- YVYPNFLCTISLMV-UHFFFAOYSA-N 7-methoxy-5-[3-(trifluoromethyl)phenyl]-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(OC)=CC=C2NC(=O)CN=C1C1=CC=CC(C(F)(F)F)=C1 YVYPNFLCTISLMV-UHFFFAOYSA-N 0.000 description 3
- PEACRWGRSQUWBX-UHFFFAOYSA-N 7-methoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC(OC)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 PEACRWGRSQUWBX-UHFFFAOYSA-N 0.000 description 3
- ZNGYNNFXIKDGEM-UHFFFAOYSA-N 8-bromo-5-(4-bromophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=CC(Br)=CC=C1C1=NCC(=O)NC2=CC(Br)=CC=C12 ZNGYNNFXIKDGEM-UHFFFAOYSA-N 0.000 description 3
- GETNXSJEFJMXMA-UHFFFAOYSA-N 8-ethoxy-1-ethyl-7-methoxy-3,5-diphenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OCC)=CC=2N(CC)C(=O)C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 GETNXSJEFJMXMA-UHFFFAOYSA-N 0.000 description 3
- RVPJDPWFXUFDQJ-UHFFFAOYSA-N 8-ethoxy-7-methoxy-1-methyl-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OCC)=CC=2N(C)C(=O)CN=C1C1=CC=CC=C1 RVPJDPWFXUFDQJ-UHFFFAOYSA-N 0.000 description 3
- SITGILNKAQWBIB-UHFFFAOYSA-N 8-ethoxy-7-methoxy-3,5-diphenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OCC)=CC=2NC(=O)C(C=2C=CC=CC=2)N=C1C1=CC=CC=C1 SITGILNKAQWBIB-UHFFFAOYSA-N 0.000 description 3
- RPSHKCWYIAQKRC-UHFFFAOYSA-N 8-ethoxy-7-methoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OCC)=CC=2NC(=O)CN=C1C1=CC=CC=C1 RPSHKCWYIAQKRC-UHFFFAOYSA-N 0.000 description 3
- OGDLFFYXUKTNDD-UHFFFAOYSA-N 8-methoxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C=1C(OC)=CC=C2C=1NC(=O)CN=C2C1=CC=CC=C1 OGDLFFYXUKTNDD-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 101150003085 Pdcl gene Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical group I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 3
- LKIOIDUSXIBIKG-UHFFFAOYSA-N methyl 12-(7,8-dimethoxy-4-oxo-1-phenyl-5h-2,3-benzodiazepin-3-yl)dodecanoate Chemical compound C12=CC(OC)=C(OC)C=C2CC(=O)N(CCCCCCCCCCCC(=O)OC)N=C1C1=CC=CC=C1 LKIOIDUSXIBIKG-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- BOMXQVJQCPAFSQ-UHFFFAOYSA-N n-[2-[2-(7,8-dimethoxy-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)phenyl]ethyl]acetamide Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(C=2C(=CC=CC=2)CCNC(C)=O)N=C1C1=CC=CC=C1 BOMXQVJQCPAFSQ-UHFFFAOYSA-N 0.000 description 3
- GSAZXWNBULMSQA-UHFFFAOYSA-N n-[3-[4-(7,8-dimethoxy-3-methyl-4-oxo-5h-2,3-benzodiazepin-1-yl)phenyl]phenyl]acetamide Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CC(NC(C)=O)=C1 GSAZXWNBULMSQA-UHFFFAOYSA-N 0.000 description 3
- WGDRQZCPBXKCEN-SFHVURJKSA-N n-[4-[(3s)-7,8-dimethoxy-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]butyl]acetamide Chemical compound N([C@@H](CCCCNC(C)=O)C(=O)NC=1C=C(C(=CC=11)OC)OC)=C1C1=CC=CC=C1 WGDRQZCPBXKCEN-SFHVURJKSA-N 0.000 description 3
- DORRTNHBBJHEEQ-UHFFFAOYSA-N n-[[2-(7,8-dimethoxy-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl)phenyl]methyl]acetamide Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(=O)C(C=2C(=CC=CC=2)CNC(C)=O)N=C1C1=CC=CC=C1 DORRTNHBBJHEEQ-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- PAQVEXAFKDWGOT-UHFFFAOYSA-N prop-2-ynoxymethylbenzene Chemical compound C#CCOCC1=CC=CC=C1 PAQVEXAFKDWGOT-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229940070710 valerate Drugs 0.000 description 3
- PRQNURIVOWEVEP-UHFFFAOYSA-N (2-amino-4,5-dimethoxyphenyl)-(2-bromophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC(N)=C1C(=O)C1=CC=CC=C1Br PRQNURIVOWEVEP-UHFFFAOYSA-N 0.000 description 2
- HXTDCSNZXQTBAD-UHFFFAOYSA-N (2-amino-4,5-dimethoxyphenyl)-(3-bromophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC(N)=C1C(=O)C1=CC=CC(Br)=C1 HXTDCSNZXQTBAD-UHFFFAOYSA-N 0.000 description 2
- WFQVKQBWROLGIR-UHFFFAOYSA-N (2-amino-4,5-dimethoxyphenyl)-(4-bromophenyl)methanone Chemical compound C1=C(OC)C(OC)=CC(N)=C1C(=O)C1=CC=C(Br)C=C1 WFQVKQBWROLGIR-UHFFFAOYSA-N 0.000 description 2
- NFTBFVFOCVDIMD-UHFFFAOYSA-N (2-amino-4-bromophenyl)-(4-bromophenyl)methanone Chemical compound NC1=CC(Br)=CC=C1C(=O)C1=CC=C(Br)C=C1 NFTBFVFOCVDIMD-UHFFFAOYSA-N 0.000 description 2
- GFHWOKUXKUUKQJ-UHFFFAOYSA-N (2-amino-4-methoxyphenyl)-phenylmethanone Chemical compound NC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 GFHWOKUXKUUKQJ-UHFFFAOYSA-N 0.000 description 2
- TWJWFECRFISHHB-UHFFFAOYSA-N (2-amino-5-ethoxy-4-methoxyphenyl)-phenylmethanone Chemical compound C1=C(OC)C(OCC)=CC(C(=O)C=2C=CC=CC=2)=C1N TWJWFECRFISHHB-UHFFFAOYSA-N 0.000 description 2
- NAKVSMGYGQEWPC-UHFFFAOYSA-N (2-amino-5-hydroxy-4-methoxyphenyl)-phenylmethanone Chemical compound C1=C(O)C(OC)=CC(N)=C1C(=O)C1=CC=CC=C1 NAKVSMGYGQEWPC-UHFFFAOYSA-N 0.000 description 2
- AFDXETYIZYYCEH-UHFFFAOYSA-N (2-amino-5-methoxyphenyl)-[3-(trifluoromethyl)phenyl]methanone Chemical compound COC1=CC=C(N)C(C(=O)C=2C=C(C=CC=2)C(F)(F)F)=C1 AFDXETYIZYYCEH-UHFFFAOYSA-N 0.000 description 2
- UKDOBSYQTBSUQR-UHFFFAOYSA-N (2-amino-5-methoxyphenyl)-phenylmethanone Chemical compound COC1=CC=C(N)C(C(=O)C=2C=CC=CC=2)=C1 UKDOBSYQTBSUQR-UHFFFAOYSA-N 0.000 description 2
- NSJVYHOPHZMZPN-UHFFFAOYSA-N (2-methylphenyl)boronic acid Chemical compound CC1=CC=CC=C1B(O)O NSJVYHOPHZMZPN-UHFFFAOYSA-N 0.000 description 2
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 2
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 2
- ALKQZAYAWNIANE-UHFFFAOYSA-N (6-amino-2,3-dihydro-1,4-benzodioxin-7-yl)-phenylmethanone Chemical compound NC1=CC=2OCCOC=2C=C1C(=O)C1=CC=CC=C1 ALKQZAYAWNIANE-UHFFFAOYSA-N 0.000 description 2
- RGGLEJFUEMKQSH-UHFFFAOYSA-N 1,4-benzodiazepin-2-one Chemical compound O=C1C=NC=C2C=CC=CC2=N1 RGGLEJFUEMKQSH-UHFFFAOYSA-N 0.000 description 2
- ZCVXDIHBWICLSH-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-5-ethyl-3,5-dihydro-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2C(CC)C(=O)NN=C1C1=CC2=CC=CC=C2S1 ZCVXDIHBWICLSH-UHFFFAOYSA-N 0.000 description 2
- MRIYEGFMPBTRHA-UHFFFAOYSA-N 1-(1-benzothiophen-2-yl)-7,8-diethoxy-5-ethyl-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2C(CC)C(=O)N(C)N=C1C1=CC2=CC=CC=C2S1 MRIYEGFMPBTRHA-UHFFFAOYSA-N 0.000 description 2
- FVZWOEXGLBRPHR-UHFFFAOYSA-N 1-(4-hept-1-ynylphenyl)-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=CC(C#CCCCCC)=CC=C1C1=NN(C)C(=O)CC2=CC(OC)=C(OC)C=C12 FVZWOEXGLBRPHR-UHFFFAOYSA-N 0.000 description 2
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 2
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 2
- KZOFGDXXMLUUFL-UHFFFAOYSA-N 1-ethyl-7,8-dimethoxy-5-[3-(2-phenylethynyl)phenyl]-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(CC)C2=CC(OC)=C(OC)C=C2C=1C(C=1)=CC=CC=1C#CC1=CC=CC=C1 KZOFGDXXMLUUFL-UHFFFAOYSA-N 0.000 description 2
- LTCUMIUUJPPJAX-UHFFFAOYSA-N 1-methoxy-5-phenyl-3h-1,4-benzodiazepin-2-one Chemical compound N=1CC(=O)N(OC)C2=CC=CC=C2C=1C1=CC=CC=C1 LTCUMIUUJPPJAX-UHFFFAOYSA-N 0.000 description 2
- LXWQJQHNSJLQTO-UHFFFAOYSA-N 10-phenyl-2,3,6,8-tetrahydro-[1,4]dioxino[2,3-h][1,4]benzodiazepin-7-one Chemical compound C12=CC=3OCCOC=3C=C2NC(=O)CN=C1C1=CC=CC=C1 LXWQJQHNSJLQTO-UHFFFAOYSA-N 0.000 description 2
- QGXNHCXKWFNKCG-UHFFFAOYSA-N 2-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC=C1C#N QGXNHCXKWFNKCG-UHFFFAOYSA-N 0.000 description 2
- IKYZLUAAOLUOFW-UHFFFAOYSA-N 3,4-diethoxyaniline Chemical compound CCOC1=CC=C(N)C=C1OCC IKYZLUAAOLUOFW-UHFFFAOYSA-N 0.000 description 2
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 2
- OGOBINRVCUWLGN-UHFFFAOYSA-N 3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC(C#N)=C1 OGOBINRVCUWLGN-UHFFFAOYSA-N 0.000 description 2
- BEFRVRWYSAQETM-UHFFFAOYSA-N 3-ethoxy-4-methoxyaniline Chemical compound CCOC1=CC(N)=CC=C1OC BEFRVRWYSAQETM-UHFFFAOYSA-N 0.000 description 2
- HQSCPPCMBMFJJN-UHFFFAOYSA-N 4-bromobenzonitrile Chemical compound BrC1=CC=C(C#N)C=C1 HQSCPPCMBMFJJN-UHFFFAOYSA-N 0.000 description 2
- IVUAAOBNUNMJQC-UHFFFAOYSA-N 5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound C12=CC=CC=C2NC(=O)CN=C1C1=CC=CC=C1 IVUAAOBNUNMJQC-UHFFFAOYSA-N 0.000 description 2
- JMAIHPNISRFSSW-UHFFFAOYSA-N 6,7-dimethoxy-1-methyl-3,1-benzoxazine-2,4-dione Chemical compound CN1C(=O)OC(=O)C2=C1C=C(OC)C(OC)=C2 JMAIHPNISRFSSW-UHFFFAOYSA-N 0.000 description 2
- AATKSLBQUSPGJS-UHFFFAOYSA-N 6,7-dimethoxy-4h-isochromene-1,3-dione Chemical compound C1C(=O)OC(=O)C2=C1C=C(OC)C(OC)=C2 AATKSLBQUSPGJS-UHFFFAOYSA-N 0.000 description 2
- BHQWWGQGYZTSJN-UHFFFAOYSA-N 7,8-dimethoxy-1,3-dimethyl-3,4-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound CN1C(=O)C(C)NC(=O)C2=C1C=C(OC)C(OC)=C2 BHQWWGQGYZTSJN-UHFFFAOYSA-N 0.000 description 2
- JNSUWWWQGPXZBN-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-(2-phenylethynyl)-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C#CC1=CC=CC=C1 JNSUWWWQGPXZBN-UHFFFAOYSA-N 0.000 description 2
- RUIDJCJYWFYLGT-UHFFFAOYSA-N 7,8-dimethoxy-1-methyl-5-thiophen-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=CS1 RUIDJCJYWFYLGT-UHFFFAOYSA-N 0.000 description 2
- HBNQJZPTBMBXCX-UHFFFAOYSA-N 7,8-dimethoxy-3,4-dihydro-1h-1,4-benzodiazepine-2,5-dione Chemical compound N1C(=O)CNC(=O)C2=C1C=C(OC)C(OC)=C2 HBNQJZPTBMBXCX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 2
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 2
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 101150098694 PDE5A gene Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BPTABBGLHGBJQR-UHFFFAOYSA-N [3,5-bis(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BPTABBGLHGBJQR-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000005024 alkenyl aryl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- FPFQPLFYTKMCHN-PPHPATTJSA-N ethyl (2s)-2-amino-3-phenylpropanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC1=CC=CC=C1 FPFQPLFYTKMCHN-PPHPATTJSA-N 0.000 description 2
- PNJYCUHMPBXTOJ-UHFFFAOYSA-N ethyl 2-(1-ethyl-7,8-dimethoxy-2-oxo-5-phenyl-3h-1,4-benzodiazepin-3-yl)acetate Chemical compound C12=CC(OC)=C(OC)C=C2N(CC)C(=O)C(CC(=O)OCC)N=C1C1=CC=CC=C1 PNJYCUHMPBXTOJ-UHFFFAOYSA-N 0.000 description 2
- DABYEOZXRSTEGL-UHFFFAOYSA-N ethyl 2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(CC(N)C(=O)OCC)=CNC2=C1 DABYEOZXRSTEGL-UHFFFAOYSA-N 0.000 description 2
- QIGLJVBIRIXQRN-UHFFFAOYSA-N ethyl 2-amino-4-methylpentanoate Chemical compound CCOC(=O)C(N)CC(C)C QIGLJVBIRIXQRN-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- PZJSZBJLOWMDRG-UHFFFAOYSA-N furan-2-ylboronic acid Chemical compound OB(O)C1=CC=CO1 PZJSZBJLOWMDRG-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- WUAXWQRULBZETB-UHFFFAOYSA-N homoveratric acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OC WUAXWQRULBZETB-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WVKIFIROCHIWAY-UHFFFAOYSA-N hydron;2-(methylamino)acetic acid;chloride Chemical compound Cl.CNCC(O)=O WVKIFIROCHIWAY-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- IYUKFAFDFHZKPI-DFWYDOINSA-N methyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](C)N IYUKFAFDFHZKPI-DFWYDOINSA-N 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- OWPIFQXNMLDXKW-UHFFFAOYSA-N tert-butyl indole-1-carboxylate Chemical compound C1=CC=C2N(C(=O)OC(C)(C)C)C=CC2=C1 OWPIFQXNMLDXKW-UHFFFAOYSA-N 0.000 description 2
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- NCMNTRBEBJCETB-UHFFFAOYSA-N (2-amino-3-bromo-4,5-dimethoxyphenyl)-phenylmethanone Chemical compound BrC1=C(OC)C(OC)=CC(C(=O)C=2C=CC=CC=2)=C1N NCMNTRBEBJCETB-UHFFFAOYSA-N 0.000 description 1
- AJCNEMCVBCSJSR-PPHPATTJSA-N (2s)-2-(ethylamino)-3-phenylpropanoic acid;hydrochloride Chemical compound Cl.CCN[C@H](C(O)=O)CC1=CC=CC=C1 AJCNEMCVBCSJSR-PPHPATTJSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- AFSSVCNPDKKSRR-UHFFFAOYSA-N (3-bromophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Br)=C1 AFSSVCNPDKKSRR-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- VYEWTHXZHHATTA-UHFFFAOYSA-N (4-acetamidophenyl)boronic acid Chemical compound CC(=O)NC1=CC=C(B(O)O)C=C1 VYEWTHXZHHATTA-UHFFFAOYSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- GZFAVYWCPSMLCM-UHFFFAOYSA-N (6-methoxynaphthalen-2-yl)boronic acid Chemical compound C1=C(B(O)O)C=CC2=CC(OC)=CC=C21 GZFAVYWCPSMLCM-UHFFFAOYSA-N 0.000 description 1
- ZVHAZMUBLCEMGG-UHFFFAOYSA-N (6-phenylmethoxynaphthalen-2-yl)boronic acid Chemical compound C1=CC2=CC(B(O)O)=CC=C2C=C1OCC1=CC=CC=C1 ZVHAZMUBLCEMGG-UHFFFAOYSA-N 0.000 description 1
- PWTFRUXTAFBWBW-UHFFFAOYSA-N 1,3-dibromo-5-(bromomethyl)benzene Chemical compound BrCC1=CC(Br)=CC(Br)=C1 PWTFRUXTAFBWBW-UHFFFAOYSA-N 0.000 description 1
- AOPMXOAOZJAEMC-UHFFFAOYSA-N 1,4-benzodiazepin-7-one Chemical compound C1=CN=CC2=CC(=O)C=CC2=N1 AOPMXOAOZJAEMC-UHFFFAOYSA-N 0.000 description 1
- FPSXKAJUOFGDNX-UHFFFAOYSA-N 1-(4-chlorophenyl)-7,8-diethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OCC)C(OCC)=CC=2CC(=O)N(C)N=C1C1=CC=C(Cl)C=C1 FPSXKAJUOFGDNX-UHFFFAOYSA-N 0.000 description 1
- GYYVSPASTBUVCR-UHFFFAOYSA-N 1-(4-chlorophenyl)-7,8-dimethoxy-3-methyl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C1=CC=C(Cl)C=C1 GYYVSPASTBUVCR-UHFFFAOYSA-N 0.000 description 1
- RGLQSFFFIREZFV-UHFFFAOYSA-N 1-(bromomethyl)-2,4-dichlorobenzene Chemical compound ClC1=CC=C(CBr)C(Cl)=C1 RGLQSFFFIREZFV-UHFFFAOYSA-N 0.000 description 1
- PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 1
- WAUNFWSVXRPCDQ-UHFFFAOYSA-N 1-(bromomethyl)-2-methoxybenzene Chemical compound COC1=CC=CC=C1CBr WAUNFWSVXRPCDQ-UHFFFAOYSA-N 0.000 description 1
- WGVYCXYGPNNUQA-UHFFFAOYSA-N 1-(bromomethyl)-2-methylbenzene Chemical compound CC1=CC=CC=C1CBr WGVYCXYGPNNUQA-UHFFFAOYSA-N 0.000 description 1
- MYYYZNVAUZVXBO-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CBr)=C1 MYYYZNVAUZVXBO-UHFFFAOYSA-N 0.000 description 1
- ZKSOJQDNSNJIQW-UHFFFAOYSA-N 1-(bromomethyl)-3-methoxybenzene Chemical compound COC1=CC=CC(CBr)=C1 ZKSOJQDNSNJIQW-UHFFFAOYSA-N 0.000 description 1
- WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical compound CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
- PKRRNTJIHGOMRC-UHFFFAOYSA-N 1-benzofuran-2-ylboronic acid Chemical compound C1=CC=C2OC(B(O)O)=CC2=C1 PKRRNTJIHGOMRC-UHFFFAOYSA-N 0.000 description 1
- ZTXYRZOIOISELI-UHFFFAOYSA-N 1-benzyl-5-chloro-7,8-dimethoxy-3h-1,4-benzodiazepin-2-one Chemical compound O=C1CN=C(Cl)C=2C=C(OC)C(OC)=CC=2N1CC1=CC=CC=C1 ZTXYRZOIOISELI-UHFFFAOYSA-N 0.000 description 1
- FRLQEZGVOSOIOV-UHFFFAOYSA-N 1-benzyl-7,8-dimethoxy-3,4-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound O=C1CNC(=O)C=2C=C(OC)C(OC)=CC=2N1CC1=CC=CC=C1 FRLQEZGVOSOIOV-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- LZSYGJNFCREHMD-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)benzene Chemical compound BrCC1=CC=CC=C1Br LZSYGJNFCREHMD-UHFFFAOYSA-N 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- BZKOZYWGZKRTIB-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-6-amine Chemical compound O1CCOC2=CC(N)=CC=C21 BZKOZYWGZKRTIB-UHFFFAOYSA-N 0.000 description 1
- UUVDOPTUDWJHFK-UHFFFAOYSA-N 2-(bromomethyl)-1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C(CBr)=C1 UUVDOPTUDWJHFK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AFMPMSCZPVNPEM-UHFFFAOYSA-N 2-bromobenzonitrile Chemical compound BrC1=CC=CC=C1C#N AFMPMSCZPVNPEM-UHFFFAOYSA-N 0.000 description 1
- NZCKTGCKFJDGFD-UHFFFAOYSA-N 2-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Br NZCKTGCKFJDGFD-UHFFFAOYSA-N 0.000 description 1
- OLAITAANNRHOLM-UHFFFAOYSA-N 2-ethoxy-5-nitrophenol Chemical compound CCOC1=CC=C([N+]([O-])=O)C=C1O OLAITAANNRHOLM-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 102000001707 3',5'-Cyclic-AMP Phosphodiesterases Human genes 0.000 description 1
- 108010054479 3',5'-Cyclic-AMP Phosphodiesterases Proteins 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- SJGGDZCTGBKBCK-UHFFFAOYSA-N 3-acetylphenylboronic acid Chemical compound CC(=O)C1=CC=CC(B(O)O)=C1 SJGGDZCTGBKBCK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- FURFVPBUGLPPFW-UHFFFAOYSA-N 3-bromobenzaldehyde hydrobromide Chemical compound Br.BrC1=CC=CC(C=O)=C1 FURFVPBUGLPPFW-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N 3-bromobenzonitrile Chemical compound BrC1=CC=CC(C#N)=C1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- RUROFEVDCUGKHD-UHFFFAOYSA-N 3-bromoprop-1-enylbenzene Chemical compound BrCC=CC1=CC=CC=C1 RUROFEVDCUGKHD-UHFFFAOYSA-N 0.000 description 1
- ZNRGSYUVFVNSAW-UHFFFAOYSA-N 3-nitrophenylboronic acid Chemical compound OB(O)C1=CC=CC([N+]([O-])=O)=C1 ZNRGSYUVFVNSAW-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- VLVCDUSVTXIWGW-UHFFFAOYSA-N 4-iodoaniline Chemical compound NC1=CC=C(I)C=C1 VLVCDUSVTXIWGW-UHFFFAOYSA-N 0.000 description 1
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- XJNPNXSISMKQEX-UHFFFAOYSA-N 4-nitrocatechol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1O XJNPNXSISMKQEX-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- POCQPJWWSXAJHM-UHFFFAOYSA-N 5-(4-chlorophenyl)-7,8-dimethoxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound C1=2C=C(OC)C(OC)=CC=2N(C)C(=O)CN=C1C1=CC=C(Cl)C=C1 POCQPJWWSXAJHM-UHFFFAOYSA-N 0.000 description 1
- HRBONWTYLGDUKT-UHFFFAOYSA-N 5-[3-(hydroxymethyl)phenyl]-7,8-dimethoxy-1-methyl-3-propyl-3h-1,4-benzodiazepin-2-one Chemical compound C12=CC(OC)=C(OC)C=C2N(C)C(=O)C(CCC)N=C1C1=CC=CC(CO)=C1 HRBONWTYLGDUKT-UHFFFAOYSA-N 0.000 description 1
- LEWTUQQUNJVNSJ-UHFFFAOYSA-N 5-chloro-7,8-dimethoxy-1,3-dimethyl-3h-1,4-benzodiazepin-2-one Chemical compound CN1C(=O)C(C)N=C(Cl)C2=C1C=C(OC)C(OC)=C2 LEWTUQQUNJVNSJ-UHFFFAOYSA-N 0.000 description 1
- VRWXHCGIOURJAL-UHFFFAOYSA-N 5-chloro-7,8-dimethoxy-1-propyl-3h-1,4-benzodiazepin-2-one Chemical compound ClC1=NCC(=O)N(CCC)C2=CC(OC)=C(OC)C=C21 VRWXHCGIOURJAL-UHFFFAOYSA-N 0.000 description 1
- SHWCMBUPQTWNES-UHFFFAOYSA-N 6,7-dimethoxy-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=C1C=C(OC)C(OC)=C2 SHWCMBUPQTWNES-UHFFFAOYSA-N 0.000 description 1
- RVDWKXIFMDTSOO-UHFFFAOYSA-N 7,8-dimethoxy-1-propyl-3,4-dihydro-1,4-benzodiazepine-2,5-dione Chemical compound O=C1NCC(=O)N(CCC)C2=CC(OC)=C(OC)C=C21 RVDWKXIFMDTSOO-UHFFFAOYSA-N 0.000 description 1
- NIDQDDGVVNCHFH-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-(4-pyridin-3-ylphenyl)-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C(C=C1)=CC=C1C1=CC=CN=C1 NIDQDDGVVNCHFH-UHFFFAOYSA-N 0.000 description 1
- FZBQSODPIDLQDZ-UHFFFAOYSA-N 7,8-dimethoxy-3-methyl-1-naphthalen-2-yl-5h-2,3-benzodiazepin-4-one Chemical compound C1=2C=C(OC)C(OC)=CC=2CC(=O)N(C)N=C1C1=CC=C(C=CC=C2)C2=C1 FZBQSODPIDLQDZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 0 COC(C(*)(*)c1ccc(*)c(*)c1)=O Chemical compound COC(C(*)(*)c1ccc(*)c(*)c1)=O 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- ICMAFTSLXCXHRK-UHFFFAOYSA-N Ethyl pentanoate Chemical compound CCCCC(=O)OCC ICMAFTSLXCXHRK-UHFFFAOYSA-N 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- PWUBONDMIMDOQY-UHFFFAOYSA-N acetonitrile;hydrochloride Chemical compound Cl.CC#N PWUBONDMIMDOQY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000005025 alkynylaryl group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- YNCYPMUJDDXIRH-UHFFFAOYSA-N benzo[b]thiophene-2-boronic acid Chemical compound C1=CC=C2SC(B(O)O)=CC2=C1 YNCYPMUJDDXIRH-UHFFFAOYSA-N 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000142 dyskinetic effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- VSCJXMLDRWWDOQ-UHFFFAOYSA-N ethoxysulfonylmethanesulfonic acid;hydrochloride Chemical compound Cl.CCOS(=O)(=O)CS(O)(=O)=O VSCJXMLDRWWDOQ-UHFFFAOYSA-N 0.000 description 1
- FNNXQLSKQSVNLL-UHFFFAOYSA-N ethyl 2-amino-2-phenylacetate;hydrochloride Chemical compound Cl.CCOC(=O)C(N)C1=CC=CC=C1 FNNXQLSKQSVNLL-UHFFFAOYSA-N 0.000 description 1
- JCXLZWMDXJFOOI-UHFFFAOYSA-N ethyl 2-aminopropanoate;hydron;chloride Chemical compound [Cl-].CCOC(=O)C(C)[NH3+] JCXLZWMDXJFOOI-UHFFFAOYSA-N 0.000 description 1
- MLSGRWDEDYJNER-UHFFFAOYSA-N ethyl 2-anilinoacetate Chemical compound CCOC(=O)CNC1=CC=CC=C1 MLSGRWDEDYJNER-UHFFFAOYSA-N 0.000 description 1
- UACSTJFVSYFIPA-UHFFFAOYSA-N ethyl acetate;hydrobromide Chemical compound Br.CCOC(C)=O UACSTJFVSYFIPA-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- SWVMLNPDTIFDDY-FVGYRXGTSA-N methyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-FVGYRXGTSA-N 0.000 description 1
- QNXOHINFQALBQN-UHFFFAOYSA-N methyl 12-bromododecanoate Chemical compound COC(=O)CCCCCCCCCCCBr QNXOHINFQALBQN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 108010028584 nucleotidase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- QVCOXWYMPCBIMH-UHFFFAOYSA-N prop-2-ynyl carbamate Chemical compound NC(=O)OCC#C QVCOXWYMPCBIMH-UHFFFAOYSA-N 0.000 description 1
- MUIMMFVCYYVISV-UHFFFAOYSA-N propan-1-ol;hydrobromide Chemical compound Br.CCCO MUIMMFVCYYVISV-UHFFFAOYSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/02—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0107458 | 2001-06-07 | ||
| PCT/FR2002/001952 WO2002098865A2 (fr) | 2001-06-07 | 2002-06-07 | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005503356A true JP2005503356A (ja) | 2005-02-03 |
| JP2005503356A5 JP2005503356A5 (enExample) | 2006-01-05 |
Family
ID=8864056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003501989A Pending JP2005503356A (ja) | 2001-06-07 | 2002-06-07 | 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7250410B2 (enExample) |
| EP (1) | EP1392663A2 (enExample) |
| JP (1) | JP2005503356A (enExample) |
| AU (2) | AU2002317910B2 (enExample) |
| CA (1) | CA2446696A1 (enExample) |
| IL (2) | IL159105A0 (enExample) |
| NZ (1) | NZ529582A (enExample) |
| WO (1) | WO2002098865A2 (enExample) |
| ZA (1) | ZA200400057B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
| US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US7572788B2 (en) * | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| JP5127096B2 (ja) | 1999-04-30 | 2013-01-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用 |
| JP2005535710A (ja) * | 2002-08-09 | 2005-11-24 | トランス テック ファーマ,インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
| NZ540167A (en) * | 2002-10-30 | 2007-06-29 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| FR2846653B1 (fr) * | 2002-10-30 | 2007-04-20 | Neuro3D | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations |
| WO2005014532A1 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| EP1548011A1 (en) * | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| US20090275099A1 (en) * | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| FR2870539B1 (fr) * | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
| AU2005272627A1 (en) | 2004-08-13 | 2006-02-23 | Amgen Inc. | Substituted benzofused heterocycles |
| US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| CA2611031A1 (en) * | 2005-06-01 | 2007-05-10 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
| US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
| AU2006308655B2 (en) | 2005-11-01 | 2010-09-23 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
| US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
| JP5264716B2 (ja) | 2006-06-09 | 2013-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物および方法 |
| AU2008226532B2 (en) | 2007-03-09 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| EP2146722A4 (en) * | 2007-05-10 | 2011-08-03 | Amr Technology Inc | ARYL AND HETEROARYL SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND THEIR USE FOR BLOCKING THE RECOVERY OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE |
| ES2614498T3 (es) * | 2007-09-14 | 2017-05-31 | The Regents Of The University Of Michigan | Inhibidores de ATPasa F1F0 y métodos relacionados |
| WO2009037302A1 (en) * | 2007-09-18 | 2009-03-26 | Via Pharmaceuticals, Inc. | 5-substituted-1, 4-benz0diazepines as phosphodiesterase inhibitors |
| US8188072B2 (en) | 2007-11-06 | 2012-05-29 | The Regents Of The University Of Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions |
| WO2010030891A2 (en) | 2008-09-11 | 2010-03-18 | The Regents Of The University Of Michigan | Aryl guanidine f1f0-atpase inhibitors and related methods |
| US8604023B2 (en) | 2009-04-17 | 2013-12-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
| JP2013505258A (ja) | 2009-09-18 | 2013-02-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ベンゾジアゼピノン化合物およびそれを使用する治療方法 |
| AU2010322287B2 (en) | 2009-11-17 | 2014-04-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| US9126978B2 (en) | 2009-11-17 | 2015-09-08 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| WO2012075456A1 (en) | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Bromodomain inhibitors and uses thereof |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9422292B2 (en) | 2011-05-04 | 2016-08-23 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| US9328117B2 (en) | 2011-06-17 | 2016-05-03 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
| SI3157928T1 (sl) | 2014-06-20 | 2019-06-28 | Constellation Pharmaceuticals, Inc. | Kristalinične oblike 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo(C)izoksazolo(4,5-E)azepin-4-il acetamida |
| US20250313537A1 (en) * | 2022-05-13 | 2025-10-09 | University Of Cincinnati | Benzodiazepine analogs and methods of use in treating cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH411910A (de) * | 1959-12-10 | 1966-04-30 | Hoffmann La Roche | Verfahren zur Herstellung von 1,4-Benzodiazepin-Derivaten |
| NL279830A (enExample) * | 1961-06-20 | |||
| US3182067A (en) * | 1964-04-09 | 1965-05-04 | Hoffmann La Roche | Benzodiazepine compounds |
| FR1497456A (fr) * | 1964-06-15 | 1967-10-13 | Clin Byla Ets | Ortho-amino aryl cétimines, composés hétérocycliques qui s'y rattachent et prépaation de ces divers corps |
| IL29988A0 (en) * | 1967-06-23 | 1968-07-25 | American Cyanamid Co | Novel 7-trifluoromethoxybenzo-1,4-diazepines |
| US3631029A (en) * | 1967-12-01 | 1971-12-28 | Sumitomo Chemical Co | Process for producing benzodiazepine derivatives |
| FR2085645A1 (en) * | 1970-04-22 | 1971-12-31 | Chimidrog | 1-phenyl-2,3-benzodiazepin-4-ones - as tranquillizers |
| US3801569A (en) * | 1973-01-15 | 1974-04-02 | Hoffmann La Roche | 7-(1,1-difluoroalkyl)-1,4-benzodiazepines |
| DE3119874A1 (de) | 1981-05-19 | 1982-12-09 | Dr. Karl Thomae Gmbh, 7950 Biberach | "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel" |
| IL93401A (en) * | 1989-03-08 | 1994-08-26 | Kali Chemie Pharma Gmbh | H1 - Indole - 2 - Carboxylic acid 1, 7 - Consolidated N -) 1, 4 - Benzodiazepine - 3 - Il (amides, their preparation and drugs containing them |
| TW221687B (enExample) * | 1992-01-24 | 1994-03-11 | Hoffmann La Roche | |
| DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| US5891871A (en) * | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
| WO2000079263A2 (en) * | 1999-06-18 | 2000-12-28 | Synt:Em S.A. | Identifying active molecules using physico-chemical parameters |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
-
2002
- 2002-06-07 AU AU2002317910A patent/AU2002317910B2/en not_active Ceased
- 2002-06-07 WO PCT/FR2002/001952 patent/WO2002098865A2/fr not_active Ceased
- 2002-06-07 US US10/479,000 patent/US7250410B2/en not_active Expired - Fee Related
- 2002-06-07 EP EP02747514A patent/EP1392663A2/fr not_active Withdrawn
- 2002-06-07 IL IL15910502A patent/IL159105A0/xx unknown
- 2002-06-07 CA CA002446696A patent/CA2446696A1/fr not_active Abandoned
- 2002-06-07 NZ NZ529582A patent/NZ529582A/en unknown
- 2002-06-07 JP JP2003501989A patent/JP2005503356A/ja active Pending
-
2003
- 2003-11-27 IL IL159105A patent/IL159105A/en not_active IP Right Cessation
-
2004
- 2004-01-06 ZA ZA200400057A patent/ZA200400057B/en unknown
-
2008
- 2008-09-18 AU AU2008221554A patent/AU2008221554A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002098865A2 (fr) | 2002-12-12 |
| IL159105A0 (en) | 2004-05-12 |
| IL159105A (en) | 2009-05-04 |
| EP1392663A2 (fr) | 2004-03-03 |
| AU2002317910B2 (en) | 2008-06-19 |
| AU2008221554A1 (en) | 2008-10-09 |
| ZA200400057B (en) | 2005-02-21 |
| CA2446696A1 (fr) | 2002-12-12 |
| US7250410B2 (en) | 2007-07-31 |
| WO2002098865A3 (fr) | 2003-02-27 |
| NZ529582A (en) | 2006-10-27 |
| US20040152888A1 (en) | 2004-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005503356A (ja) | 環状ヌクレオチドホスホジエステラーゼ阻害剤、その製造および使用 | |
| US6635638B2 (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
| ES2315546T3 (es) | Inhibidores delas fosfodiesterasas de los nucleotidos ciclicos, que presentan una estructura de benzodiazepina, y su uso en terapia. | |
| US7410963B2 (en) | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof | |
| KR20140015267A (ko) | 진통, 정신질환, 인지장애 또는 알츠하이머병의 치료용 알파-7 니코틴 수용체 수식물질 | |
| JPH10510247A (ja) | ジヒドロピリミジン類およびその使用 | |
| SK16972002A3 (sk) | Beta-karbolínové deriváty použiteľné ako inhibítory fosfodiesterázy | |
| EP1085871A1 (en) | QUINAZOLINONE INHIBITORS OF cGMP PHOSPHODIESTERASE | |
| JPH0413347B2 (enExample) | ||
| JPH09500397A (ja) | ベンゾジアゼピン類 | |
| KR20130094311A (ko) | P2x4 수용체 길항제 | |
| CA2481855A1 (en) | Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators | |
| GB2298198A (en) | Pyrrolo-pyridine derivatives | |
| KR20110107863A (ko) | Glyt-1 억제제로서 아로일아미노- 및 헤테로아로일아미노-치환된 피페리딘 | |
| KR20010072262A (ko) | 삼환식 카르복스아미드 | |
| FR2846653A1 (fr) | Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations | |
| KR20050100695A (ko) | 2-아미노에틸 치환된 피리미딘-2-온, 사이클로프로판,피라졸린, 피리미딘 및 벤조티아제핀, 및 이들의 유로텐신ⅱ 및 소마토스타틴 5 리셉터의 리간드로서의 용도 | |
| HU224438B1 (hu) | Benzodiazepin-származékok, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények | |
| HU189679B (en) | Process for producing condensed pyrrolinone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090310 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090511 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090915 |